Incyte's INCA033989 shows spleen, symptom and anemia responses in Phase 1 myelofibrosis studies

PUBT · 1d ago
Incyte's INCA033989 shows spleen, symptom and anemia responses in Phase 1 myelofibrosis studies
  • Incyte will present new hematology data at the American Society of Hematology meeting in New Orleans, December 12-15, 2026.
  • Phase 1 INCA033989 results showed improved spleen enlargement, symptoms and anemia in myelofibrosis patients, with favorable tolerability in those without prior JAK-inhibitor treatment.
  • In essential thrombocythemia, Phase 1 studies showed INCA033989 produced molecular responses and restored normal blood cell production, extending previously presented datasets.
  • Long-term Phase 1/2 latarcibart results will assess bleeding prevention in adolescents and adults with von Willebrand disease.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202611040900BIZWIRE_USPR_____20261104_BW662877) on November 04, 2026, and is solely responsible for the information contained therein.